| Autor: |
Botond Lakatos, Bálint Gergely Szabó, Ilona Bobek, Noémi Kiss-Dala, Zsófia Gáspár, Alexandra Riczu, Borisz Petrik, Balázs Ferenc Farkas, Gabriella Sebestyén, László Gopcsa, Gabriella Bekő, János Sinkó, Péter Reményi, János Szlávik, Dóra Mathiász, István Vályi-Nagy |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 125, Iss , Pp 233-240 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2022.10.037 |
| Popis: |
Objectives: Our aim was to compare outcomes of hospitalized adults with severe COVID-19 and cytokine storm treated with tocilizumab or baricitinib. Methods: A prospective, investigational, real-world study was performed from April 2020 to April 2021 at our center. COVID-19 severity was classified by World Health Organization criteria, and cytokine storm was documented along predefined criteria. Eligible patients were enrolled at diagnosis if they fulfilled a priori inclusion criteria and received standard-of-care plus tocilizumab or baricitinib for >48 hours. Patients were followed per protocol for 28 days post-diagnosis. The primary outcome was all-cause mortality; secondary outcomes were invasive mechanical ventilation and major infectious complications. Results: Of 463 patients, 102/463 (22.1%) received tocilizumab, and 361/463 (77.9%) baricitinib. Baseline characteristics were balanced. At 28 days, there was no difference in all-cause mortality (22/102, 21.6% vs 64/361, 17.7%; P-value = 0.38). Requirement for invasive mechanical ventilation was more frequent after tocilizumab (52/102, 50.9% vs 96/361, 26.6%; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
